PIM-35: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== PIM-35 == | |||
[[File:PIM-35_structure.png|thumb|right|Chemical structure of PIM-35]] | |||
PIM-35 | '''PIM-35''' is a chemical compound that belongs to the class of [[phosphoinositide 3-kinase]] (PI3K) inhibitors. It is primarily studied for its potential therapeutic applications in the treatment of various [[cancer]]s and [[inflammatory disease]]s. PIM-35 is known for its ability to selectively inhibit specific isoforms of PI3K, which are enzymes involved in cellular functions such as growth, proliferation, and survival. | ||
== | == Mechanism of Action == | ||
PIM-35 | PIM-35 functions by targeting the PI3K signaling pathway, which is crucial for many cellular processes. The PI3K pathway is activated by various [[growth factor]]s and [[cytokine]]s, leading to the production of [[phosphatidylinositol (3,4,5)-trisphosphate]] (PIP3). PIP3 acts as a second messenger, activating downstream signaling proteins such as [[AKT]] and [[mTOR]], which promote cell survival and growth. | ||
By inhibiting PI3K, PIM-35 reduces the levels of PIP3, thereby decreasing the activation of AKT and mTOR. This results in the induction of [[apoptosis]] (programmed cell death) and inhibition of cell proliferation, making PIM-35 a promising candidate for cancer therapy. | |||
== Applications in Cancer Therapy == | |||
The PI3K pathway is often dysregulated in cancer, leading to uncontrolled cell growth and survival. PIM-35 has shown potential in preclinical studies for the treatment of various types of cancer, including [[breast cancer]], [[lung cancer]], and [[leukemia]]. Its ability to selectively inhibit specific PI3K isoforms allows for targeted therapy, potentially reducing side effects associated with non-selective PI3K inhibitors. | |||
== Research and Development == | |||
* [[ | Research on PIM-35 is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetics. Clinical trials are being conducted to evaluate its potential as a monotherapy or in combination with other anticancer agents. The development of PIM-35 is part of a broader effort to create targeted therapies that can improve outcomes for patients with cancer and other diseases involving the PI3K pathway. | ||
* [[ | == Related Pages == | ||
* [[Phosphoinositide 3-kinase]] | |||
* [[Cancer]] | |||
* [[Apoptosis]] | * [[Apoptosis]] | ||
* [[ | * [[Signal transduction]] | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:Cancer research]] | |||
[[Category:Cancer]] | |||
Latest revision as of 03:41, 13 February 2025
PIM-35[edit]
PIM-35 is a chemical compound that belongs to the class of phosphoinositide 3-kinase (PI3K) inhibitors. It is primarily studied for its potential therapeutic applications in the treatment of various cancers and inflammatory diseases. PIM-35 is known for its ability to selectively inhibit specific isoforms of PI3K, which are enzymes involved in cellular functions such as growth, proliferation, and survival.
Mechanism of Action[edit]
PIM-35 functions by targeting the PI3K signaling pathway, which is crucial for many cellular processes. The PI3K pathway is activated by various growth factors and cytokines, leading to the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 acts as a second messenger, activating downstream signaling proteins such as AKT and mTOR, which promote cell survival and growth.
By inhibiting PI3K, PIM-35 reduces the levels of PIP3, thereby decreasing the activation of AKT and mTOR. This results in the induction of apoptosis (programmed cell death) and inhibition of cell proliferation, making PIM-35 a promising candidate for cancer therapy.
Applications in Cancer Therapy[edit]
The PI3K pathway is often dysregulated in cancer, leading to uncontrolled cell growth and survival. PIM-35 has shown potential in preclinical studies for the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. Its ability to selectively inhibit specific PI3K isoforms allows for targeted therapy, potentially reducing side effects associated with non-selective PI3K inhibitors.
Research and Development[edit]
Research on PIM-35 is ongoing, with studies focusing on its efficacy, safety, and pharmacokinetics. Clinical trials are being conducted to evaluate its potential as a monotherapy or in combination with other anticancer agents. The development of PIM-35 is part of a broader effort to create targeted therapies that can improve outcomes for patients with cancer and other diseases involving the PI3K pathway.
